The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
An article from
Dive Brief
//
Obesity drugs
The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
CVS Caremark adds Zepbound and Foundayo to formulary
CVS Caremark to cover Foundayo, Zepbound obesity drugs - UPI.com
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
CVS expands access to blockbuster weight-drugs in surprise reversal
CVS Caremark will cover Lilly’s weight loss drug Zepbound once again
CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo
Lilly's Foundayo and Zepbound to gain CVS coverage, lifting sales outlook
Foundayo and Zepbound now covered for millions of Americans
The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be…
CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several months,…
CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.
This move marks a pivotal shift for patients seeking access to these highly sought-after treatments
The pharmacy benefits manager also plans to add the weight loss pill Foundayo to its formulary next month.
The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will
